Pan-sarbecovirus vaccine - SK bioscience
Alternative Names: GBP-511Latest Information Update: 04 Feb 2026
At a glance
- Originator SK Bioscience
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 29 Jan 2026 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in Australia (IM) (NCT07280858)
- 15 Oct 2025 Preclinical trials in COVID-2019 infections (Prevention) in South Korea (unspecified route)
- 15 Oct 2025 SK bioscience files an clinical trial application in Australia for phase-I/II trial for COVID-2019 infection (prevention)